Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL595428 | 0.88 | ALDH1A1 (0.48) | SMN1; SMN2LMNAALDH1A1HPGDMAPT | |
| SCHEMBL21282840 | 0.85 | CXCR2 (0.38) | SMN1; SMN2LMNAALDH1A1HPGDMAPT | |
| SCHEMBL21274721 | 0.84 | CXCR2 (0.40) | SMN1; SMN2LMNAALDH1A1HPGDMAPT | |
| SCHEMBL3950023 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAALDH1A1HPGDMAPT | |
| SCHEMBL21273912 | 0.79 | HSP90AA1 (0.50) | LMNAALDH1A1HPGDMAPTHASPIN | |
| SCHEMBL13464342 | 0.79 | ALDH1A1 (0.44) | SMN1; SMN2LMNAALDH1A1HPGDMAPT | |
| SCHEMBL29388389 | 0.79 | ALDH1A1 (0.44) | SMN1; SMN2LMNAALDH1A1HPGDMAPT | |
| SCHEMBL29241996 | 0.79 | USP2 (0.54) | SMN1; SMN2LMNAALDH1A1HPGDMAPT | |
| SCHEMBL13192768 | 0.78 | ALDH1A1 (0.43) | SMN1; SMN2LMNAALDH1A1HPGDMAPT | |
| SCHEMBL11799528 | 0.78 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAALDH1A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152111-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | ASTRAZENECA UK LIMITED (GB) | 2015-06-04 | — | — | US | claimed |
| US-20140296258-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITON | ASTRAZENECA UK LIMITED (GB) | 2014-10-02 | — | — | US | claimed |
| US-20130109702-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | ASTRAZENECA AB (GB) | 2013-05-02 | — | — | US | claimed |
| US-20130072503-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | ASTRAZENECA (GB) | 2013-03-21 | — | — | US | claimed |
| US-20120165348-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | claimed |
| EP-2322513-A2 | Intermediates | AstraZeneca AB (SE) | 2011-05-18 | — | — | EP | claimed |
| US-20100069408-A1 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition | ASTRAZENECA AB (SE) | 2010-03-18 | — | — | US | claimed |
| US-20060025590-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2006-02-02 | — | — | US | claimed |
| EP-1386921-A1 | Intermediates | AstraZeneca AB (SE) | 2004-02-04 | — | — | EP | claimed |
| US-20030144305-A1 | Novel compounds | ASTRAZENECA AB | 2003-07-31 | — | — | US | claimed |
| EP-1135391-A1 | NOVEL TRIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2001-09-26 | — | — | EP | claimed |
| WO-2000034283-A1 | NOVEL TRIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-06-15 | — | — | WO | claimed |
| CN-113329753-B | Pyrimidine derivatives for the prevention and treatment of gram-negative bacterial infections, pollution and fouling | 列日大学 | 2024-08-13 | — | — | CN | disclosed |
| CN-111386271-B | Pyrimidine derivatives for the prevention and treatment of bacterial infections | 列日大学 | 2023-05-30 | — | — | CN | disclosed |
| EP-3752506-B1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS | UNIV LIEGE (BE) | 2022-12-14 | — | — | EP | disclosed |
| US-20210290625-A1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | Université de Liège (BE) | 2021-09-23 | — | — | US | disclosed |
| US-20030144305-A1 | Novel compounds | ASTRAZENECA AB | 2003-07-31 | — | — | US | disclosed |
| US-6525060-B1 | P2T (P2YADP or P2TAC) receptor antagonists; anticoagulant, antithrombotic | ASTRAZENECA UK LIMITED (GB) | 2003-02-25 | — | — | US | disclosed |
| EP-1135391-A1 | NOVEL TRIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000034283-A1 | NOVEL TRIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165348-A1 | Novel compounds | P2RX5, P2RX4, P2RY4 | SMN1; SMN2 4576/4885LMNA 2647/4885ALDH1A1 2868/4885 |
| US-20060025590-A1 | Novel compounds | P2RX5, P2RX4, P2RY4 | SMN1; SMN2 4576/4885LMNA 2647/4885ALDH1A1 2868/4885 |
| US-20150152111-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | THPO, PF4, P2RY4 | SMN1; SMN2 4610/4885LMNA 4157/4885ALDH1A1 1707/4885 |
| US-20210290625-A1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | PIGS, TYMP, TYMS | SMN1; SMN2 4821/4885LMNA 3843/4885ALDH1A1 3643/4885 |
| US-20100069408-A1 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition | THPO, PF4, P2RY4 | SMN1; SMN2 4610/4885LMNA 4157/4885ALDH1A1 1707/4885 |
| US-20140296258-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITON | GP6, THPO, P2RY6 | SMN1; SMN2 4556/4885LMNA 3921/4885ALDH1A1 2083/4885 |
| US-20030144305-A1 | Novel compounds | DPYD, TYMP, NUDT15 | SMN1; SMN2 3878/4885LMNA 4158/4885ALDH1A1 2063/4885 |
| US-20130072503-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | THPO, PF4, P2RY4 | SMN1; SMN2 4610/4885LMNA 4157/4885ALDH1A1 1707/4885 |
| US-20130109702-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | THPO, PF4, P2RY4 | SMN1; SMN2 4610/4885LMNA 4157/4885ALDH1A1 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.